These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2006-000445-19 Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy. A randomized multicenter phase II trial 2018-08-13 bad-data
Ongoing 2007-001108-19 Master protocol for mantle cell lymphoma. A multicenter phase II trial testing Everolimus ( RAD001) for the treatment of patients with relapsed or thérapy resistant mantle cell lymphoma. Protocol SAKK... not-yet-due
Listed as ongoing, but also has a completion date 2007-002047-24 Trial SAKK 56/07 Dasatinib first-line treatment in gastrointestinal stromal tumors. A multicenter phase II trial. 2018-05-16 bad-data
Ongoing 2007-003977-22 Protocol SAKK 77/06 and SASL 23 Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma A multicenter phase II trial not-yet-due
Ongoing 2008-006012-38 Neoadjuvant radiotherapy and capecitabine with or without panitumumab in patients with advanced, K-ras unmutated rectal cancer. A randomized multicenter phase II trial. not-yet-due
Exempt 2008-006312-38 Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced, K-ras mutated rectal cancer. A randomized multicenter phase I/II trial. not-yet-due
Listed as ongoing, but also has a completion date 2009-011884-35 Sorafenib alone or in combination with everolimus in patients with unresectable hepatocellular carcinoma. A randomized multicenter phase II trial. 2016-03-18 bad-data
Listed as ongoing, but also has a completion date 2009-016584-10 Multimodal therapy with and without cetuximab in patients with locally advanced esophageal carcinoma. An open-label phase III trial 2018-12-09 bad-data
Not reported 2010-019965-27 Fulvestrant with or without AZD6244, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor: a randomized placebo-controll... 2016-09-15 due-trials
Ongoing 2010-021253-39 Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy. A randomized, open-label, multicentre phase II trial. not-yet-due
Reported results Terminated 2011-002965-39 Orteronel maintenance therapy in patients with metastatic castration resistant prostate cancer and non-progressive disease after first-line docetaxel therapy: A multicenter randomized double-blind pla... 2016-07-20 due-trials
Ongoing 2011-005840-87 Carboplatin chemotherapy and involved node radiotherapy in stage IIA/B seminoma not-yet-due
Ongoing 2014-001189-87 Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks - A Non-Inferiority Phase III trial not-yet-due
Ongoing 2014-003893-17 Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; not-yet-due
Ongoing 2014-005330-58 A phase I/II open label clinical trial assessing safety and efficacy of intravesical instillation of VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after standard BCG therapy not-yet-due
Ongoing 2015-001482-57 Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial not-yet-due
Ongoing 2015-001487-19 Protocol SAKK 35/14 not-yet-due
Ongoing 2016-003599-39 PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients with Prostate Cancer after Prostatectomy not-yet-due
Ongoing 2016-003996-23 ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents and non-progressive disease after subsequent treatmen... not-yet-due
Ongoing 2017-003565-10 Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer. A multicenter, single-arm phase II Trial. not-yet-due